We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| N4 Pharma Plc | N4P | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.70 | 11:42:36 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.70 | 0.675 | 0.70 | 0.70 | 0.70 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 28/1/2025 11:54 by viking24 Investor meet company event in Feb |
Posted at 07/11/2024 22:34 by mello2024 Just to let shareholders and prospective investors know that N4 Pharma will be presenting at Mello's 10-year anniversary show on Tuesday 19th November 2024 9am - 7pm. The Budget is out, Mello is in! To celebrate our 10 Year Anniversary, we have created a two-day investor conference that will include top quality keynote speakers including but not limited to Peter Pereira Gray, Paul Hill, Ben Rogoff, Rosemary Banyard and Gervais Williams. Also featuring panel sessions such as our popular Mello BASH (Buy, Avoid, Sell, Hold) with professional investors and analysts such as Leon Boros, Mark Simpson and Paul Scott. There will be over 40 exhibiting companies and over 60 presentations from companies such as The Property Franchise Group, Time Finance, Brave Bison, Mortgage Advice Bureau, Aeorema and many more! Get 50% off your ticket with code MMTADVFN50. Tickets are still available: |
Posted at 19/7/2024 10:27 by earwacks Orphan drug status in USA. Effectively a patent in September. Then clinical trials for Nanogenics early next year. You can join investor hub online to keep in touch with company progress or lack of it! |
Posted at 18/4/2024 06:09 by jakleeds 18 April 2024N4 Pharma plc ("N4 Pharma" or the "Company") Oral Delivery Update N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide a further positive update on its ongoing oral delivery research work. The Company, through its research program with the University of Queensland, has undertaken further testing, in vivo, to show the successful delivery of a Nuvec® capsule into the intestine where it has released its plasmid DNA payload to produce localised protein expression. This work further demonstrates the potential of Nuvec® as an oral delivery system for multiple nucleotide payloads. Specifically, in this experiment an enterically coated capsule containing PEGylated Nuvec® loaded with a plasmid DNA expressing ovalbumin was administered on day 0 and subsequent capsules on day 3, day 6, day 9 and a booster capsule at day 21. Protein expression was significantly higher than control (DNA alone and non-PEGylated DNA loaded Nuvec®) up until day 25 which subsequently dropped away by day 36. In addition, a significantly higher ovalbumin antibody response was measured at day 36 in the PEGylated Nuvec® sample compared to control. Nigel Theobald, Chief Executive Officer of the Company, commented: "This work once more clearly shows that Nuvec® has the potential to be developed as an oral delivery system for plasmid DNA, mRNA or siRNA with many potential applications such as a vaccination with plasmid DNA or to deliver a local product for Irritable Bowel Disease or to treat colonic cancer among many possible examples. "We will continue to scope out the work needed to explore a potential development program focusing on a specific oral application and further news on this will be announced when a program is identified. In the meantime, the University of Queensland will continue its work as part of our ARC funded grant with them." For more information please contact: N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director Engage with us directly at N4 Pharma Investor Hub |
Posted at 23/2/2024 13:32 by nobbygnome I really apologise to the other users of this thread because the BBM Sheedy has turned up. He is like a cancer on these boards because everywhere he goes ends up in the gutter!I recommend you filter him like I do although that is easier said than done because he has about 30 aliases which chat to each other all day. Yes he really is that sad although of course his intention is to deceive and manipulate naive investors into thinking there is a large group of people who have the same moronic views. Yes I know, it’s absolutely pathetic…. |
Posted at 21/2/2024 15:15 by dplewis1 Not that it's much use, but Nigel responded on the investor hub.. "all work before clinical trials is defined as pre-clinical whether it is formulation work or in-vitro / in-vivo testing". So to say this is months away from clinical trials is simply not correct given they are only just doing formulation and sequence selection to prepare for testing in pre-clinical trials. |
Posted at 20/2/2024 17:56 by dplewis1 I asked a question on the investor site, seems like Dave telling porkies again "i cannot comment on speculation from any shareholder as to what they or others are posting on bulletin boards" |
Posted at 19/2/2024 08:37 by nobbygnome What a strange comment. I have a scientific interest and hopefully I am helping fellow investors to understand the issues…. |
Posted at 19/2/2024 07:44 by featherby81 You’ve spend 24 years posting nearly 32,000 times Nobby, you know how trading works better than you know how Nuvec works. You once thought it was loaded internally until I corrected you!You’re here waiting for some glimmer of hope, a collab or trial news. You’ll add and begin to ramp the hell out of it as you have in many other stocks. Once again, ADVFN is a no go area for investors to discuss the science. |
Posted at 19/2/2024 07:12 by dplewis1 The share price is heading towards half a penny .. absolutely nothing to do with "derampers" and everything to do with N4 failing at every stage. It shouldn't be a listed company, completely pointless waste of investors time and money |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
